Related references
Note: Only part of the references are listed.A comparison of deterministic and stochastic approaches for sensitivity analysis in computational systems biology
Giulia Simoni et al.
BRIEFINGS IN BIOINFORMATICS (2020)
Review: Mathematical Modeling of Prostate Cancer and Clinical Application
Tin Phan et al.
APPLIED SCIENCES-BASEL (2020)
Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou et al.
PHARMACOLOGY & THERAPEUTICS (2019)
NK cells: An attractive candidate for cancer therapy
Behnaz Valipour et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Stochastic simulation algorithms for computational systems biology: Exact, approximate, and hybrid methods
Giulia Simoni et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2019)
Immunotherapy for Prostate Cancer
Nicholas J. Venturini et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy
Adriana C. Vidal et al.
CANCER EPIDEMIOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
MDSC; the Most Important Cell You Have Never Heard Of
R. J. Tesi
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Alexander David Barrow et al.
CANCERS (2019)
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities
Erica L. Bradshaw et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Natural killer cells for cancer immunotherapy: a new CAR is catching up
[Anonymous]
EBIOMEDICINE (2019)
A Review of Cell-Based Computational Modeling in Cancer Biology
John Metzcar et al.
JCO CLINICAL CANCER INFORMATICS (2019)
The 5-formyltetrahydrofolate futile cycle reduces pathway stochasticity in an extended hybrid-stochastic model of folate-mediated one-carbon metabolism
Karla Misselbeck et al.
SCIENTIFIC REPORTS (2019)
The Tumor Immune Contexture of Prostate Cancer
Natasha Vitkin et al.
FRONTIERS IN IMMUNOLOGY (2019)
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise
Semini Sumanasuriya et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer
Elysia C. Saputra et al.
CANCER RESEARCH (2018)
Combination therapies and intra-tumoral competition: Insights from mathematical modeling
Elena Piretto et al.
JOURNAL OF THEORETICAL BIOLOGY (2018)
Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies
Seyed Peyman Shariatpanahi et al.
JOURNAL OF THEORETICAL BIOLOGY (2018)
Integrated quantitative systems pharmacology (QSP) model of lysosomal diseases provides an innovative computational platform to support research and therapeutic development for the sphingolipidoses
Chanchala Kaddi et al.
MOLECULAR GENETICS AND METABOLISM (2018)
A closed-loop multi-level model of glucose homeostasis
Cansu Uluseker et al.
PLOS ONE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Mathematical models of tumor cell proliferation: A review of the literature
Angela M. Jarrett et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Richard P. Tobin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.
Julie Nicole Graff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto et al.
NATURE (2018)
Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location
Harold Evelyn Taitt
AMERICAN JOURNAL OF MENS HEALTH (2018)
An Introduction to the Mathematical Modeling in the Study of Cancer Systems Biology
Abdallah K. Alameddine et al.
CANCER INFORMATICS (2018)
An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol
Milad Qomlaqi et al.
MATHEMATICAL BIOSCIENCES (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model
Xiulan Lai et al.
PLOS ONE (2017)
Combining immunotherapies for the treatment of prostate cancer
Jason M. Redman et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
A hybrid stochastic model of folate-mediated one-carbon metabolism: Effect of the common C677T MTHFR variant on de novo thymidylate biosynthesis
Karla Misselbeck et al.
SCIENTIFIC REPORTS (2017)
Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Andrew L. Laccetti et al.
CURRENT OPINION IN UROLOGY (2017)
Immunotherapy of Prostate Cancer: Facts and Hopes
Marijo Bilusic et al.
CLINICAL CANCER RESEARCH (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7)
Shin-Jen Lin et al.
CANCER LETTERS (2017)
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
Mark Scholz et al.
IMMUNOTARGETS AND THERAPY (2017)
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Guocan Wang et al.
CANCER DISCOVERY (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity
Christine Pasero et al.
CANCER RESEARCH (2016)
Synergistic immunologic targets for the treatment of prostate cancer
Karen M. Doersch et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
F. C. Hamdy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prediction of treatment efficacy for prostate cancer using a mathematical model
Huiming Peng et al.
SCIENTIFIC REPORTS (2016)
A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy
Luca Marchetti et al.
SCIENTIFIC REPORTS (2016)
Mathematical Models of Androgen Resistance in Prostate Cancer Patients under Intermittent Androgen Suppression Therapy
Javier Baez et al.
APPLIED SCIENCES-BASEL (2016)
A Model Qualification Method for Mechanistic Physiological QSP Models to Support Model-Informed Drug Development
C. M. Friedrich
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Immune checkpoint inhibitors and prostate cancer: a new frontier?
Alessandra Modena et al.
ONCOLOGY REVIEWS (2016)
Presence of myeloid-derived suppressor cells (MDSC) in patients with metastatic castration-sensitive and castration-resistant prostate cancer.
Karen A. Autio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Natural killer cell immunotherapy: from bench to bedside
Anna Domogala et al.
FRONTIERS IN IMMUNOLOGY (2015)
A Quantitative Systems Pharmacology Perspective on Cancer Immunology
Christina Byrne-Hoffman et al.
PROCESSES (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
Alejandro J. Garcia et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Diletta Di Mitri et al.
NATURE (2014)
A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Nicholas Mitsiades
CANCER RESEARCH (2013)
MATHEMATICAL MODELING OF REGULATORY T CELL EFFECTS ON RENAL CELL CARCINOMA TREATMENT
Lisette de Pillis et al.
DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B (2013)
TGF-β Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of PI3K/AKT/mTOR Pathway
BaoHan T. Vo et al.
ENDOCRINOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors
O. Demin et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
Shuai Tang et al.
CANCER RESEARCH (2012)
Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications
Laure Farnault et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Modeling Prostate Cancer in Mice: Limitations and Opportunities
Patrick J. Hensley et al.
JOURNAL OF ANDROLOGY (2012)
A mathematical model of tumor-immune interactions
Mark Robertson-Tessi et al.
JOURNAL OF THEORETICAL BIOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
GenSSI: a software toolbox for structural identifiability analysis of biological models
Oana Chis et al.
BIOINFORMATICS (2011)
Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models
Raluca Eftimie et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2011)
Sensitivity analysis approaches applied to systems biology models
Z. Zi
IET SYSTEMS BIOLOGY (2011)
Natural Killer Cells and Solid Tumors
Ana Stojanovic et al.
JOURNAL OF INNATE IMMUNITY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
In situ Vaccination Combined with Androgen Ablation and Regulatory T-Cell Depletion Reduces Castration-Resistant Tumor Burden in Prostate-Specific Pten Knockout Mice
Elizabeth J. Akins et al.
CANCER RESEARCH (2010)
Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer
Yoshito Hirata et al.
JOURNAL OF THEORETICAL BIOLOGY (2010)
Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models
Natalie Kronik et al.
PLOS ONE (2010)
The Role of Transforming Growth Factor-β-Mediated Tumor-Stroma Interactions in Prostate Cancer Progression: An Integrative Approach
David Basanta et al.
CANCER RESEARCH (2009)
Mathematical Model Creation for Cancer Chemo-Immunotherapy
Lisette de Pillis et al.
Computational and Mathematical Methods in Medicine (2009)
Regulatory T cells: how do they suppress immune responses?
Shimon Sakaguchi et al.
INTERNATIONAL IMMUNOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
Ilaria Marigo et al.
IMMUNOLOGICAL REVIEWS (2008)
A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer
Aiko Miyamura Ideta et al.
JOURNAL OF NONLINEAR SCIENCE (2008)
On the foundations of cancer modelling: Selected topics, speculations, and perspectives
N. Bellomo et al.
MATHEMATICAL MODELS & METHODS IN APPLIED SCIENCES (2008)
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer
Yukiko Kiniwa et al.
CLINICAL CANCER RESEARCH (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
Andrew J. Stephenson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
PA Antony et al.
JOURNAL OF IMMUNOTHERAPY (2005)
CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction
P Trzonkowski et al.
CLINICAL IMMUNOLOGY (2004)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results
KA Roehl et al.
JOURNAL OF UROLOGY (2004)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Share Paper
